Stay updated with breaking news from Syngeneic Model. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Global Preclinical Oncology Models market will be valued at US$ 1.02 Billion in 2021. It is expected to reach US$ 2.46 Billion by 2030
Preclinical Oncology Models Market Research Insight 2022| Industry Development – Growth Opportunities in Future, Revenue Forecast Up to 2030
Novartis Pharma AG: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study 177 Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or death (median rPFS benefit of 5 months) compared to best standard of care alone 1 Significant improvement demonstrated in all key secondary endpoints, including time to first symptomatic skeletal event,...
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study -- Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or death (median rPFS benefit of 5 months) compared to best standard of care alone[1] -- Significant improvement demonstrated in all key secondary endpoints, including time to first symptomatic skeletal eve...